[ELGX] Endologix, Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 7.19 Change: 0.12 (1.63%)
Ext. hours: Change: 0 (0%)

chart ELGX

Refresh chart

Strongest Trends Summary For ELGX

ELGX is in the medium-term down -50% below S&P in 3 months. In the long-term down -85% below S&P in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States, Europe, and rest of the world. It provides minimally-invasive endovascular repair (EVAR) products that consist of stent graft and catheter delivery system under the Powerlink, IntuiTrak, AFX, and VELA brand names. The company also offers endovascular sealing product that is based on the Nellix platform to seal the aneurysm, as well as provides blood flow to the legs through two blood lumens. In addition, it offers aortic extensions and limb extensions, which attach to the main body of its EVAR device, enabling physicians to customize it to fit the patient?s anatomy; and accessories, including guidewires, snares, and catheter introducer sheaths that facilitate the optimal delivery of its EVAR products. Endologix, Inc. sells its products through direct sales force, a network of agents, and independent distributors. The company was formerly known as Radiance Medical Sys

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -4.32% Sales Growth - Q/Q-5.6% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-20.58% ROE-42.54% ROI-24.29%
Current Ratio5.04 Quick Ratio3.76 Long Term Debt/Equity0.64 Debt Ratio0.24
Gross Margin71.79% Operating Margin-22.18% Net Profit Margin-32.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.61 M Cash From Investing Activities4.2 M Cash From Operating Activities-11.73 M Gross Profit26.91 M
Net Profit-11.21 M Operating Profit-9.76 M Total Assets237.76 M Total Current Assets138.41 M
Total Current Liabilities27.45 M Total Debt71.27 M Total Liabilities122.76 M Total Revenue36.67 M
Technical Data
High 52 week9.09 Low 52 week0.93 Last close3.47 Last change-0.57%
RSI39.69 Average true range0.25 Beta0.57 Volume321.74 K
Simple moving average 20 days-6.81% Simple moving average 50 days-27.27% Simple moving average 200 days-44.46%
Performance Data
Performance Week5.15% Performance Month-21.85% Performance Quart-48.82% Performance Half-42.64%
Performance Year110.3% Performance Year-to-date-51.54% Volatility daily4.71% Volatility weekly10.52%
Volatility monthly21.56% Volatility yearly74.69% Relative Volume109.64% Average Volume223.55 K
New High New Low


2019-11-11 16:01:00 | Endologix, Inc. to Present at the Stifel Healthcare Conference

2019-11-07 08:57:42 | Edited Transcript of ELGX earnings conference call or presentation 6-Nov-19 9:30pm GMT

2019-11-06 18:15:11 | Endologix ELGX Reports Q3 Loss, Tops Revenue Estimates

2019-11-06 16:01:00 | Endologix Reports Third Quarter 2019 Financial Results

2019-10-30 10:34:02 | Endologix ELGX Expected to Beat Earnings Estimates: Should You Buy?

2019-10-29 07:01:00 | Endologix, Inc. Comments on Recent FDA Update on Type III Endoleaks with AFX® Endovascular AAA System

2019-10-24 16:01:00 | Endologix, Inc. to Announce Third Quarter 2019 Financial Results on November 6, 2019

2019-10-12 09:58:14 | Should You Take Comfort From Insider Transactions At Endologix, Inc. NASDAQ:ELGX?

2019-09-16 16:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-08-26 07:42:00 | 4 Defensible Healthcare Stocks Gaining While the Market Falls

2019-08-13 13:35:20 | Health Check: How Prudently Does Endologix NASDAQ:ELGX Use Debt?

2019-08-13 00:28:49 | Edited Transcript of ELGX earnings conference call or presentation 8-Aug-19 8:30pm GMT

2019-08-08 17:15:09 | Endologix ELGX Reports Q2 Loss, Tops Revenue Estimates

2019-08-08 16:05:00 | Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market

2019-08-08 16:03:00 | Endologix Receives IDE Approval for the Nellix Chimney EndoVascular Aneurysm Sealing Protocol

2019-08-08 16:01:00 | Endologix Reports Second Quarter 2019 Financial Results

2019-08-01 10:33:02 | Will Endologix ELGX Report Negative Earnings Next Week? What You Should Know

2019-07-15 16:01:00 | Endologix, Inc. to Announce Second Quarter 2019 Financial Results on August 8, 2019

2019-07-11 16:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-06-20 08:34:12 | Endologix, Inc. ELGX Shares March Higher, Can It Continue?

2019-06-20 06:29:20 | Investors Who Bought Endologix NASDAQ:ELGX Shares Five Years Ago Are Now Down 95%

2019-06-17 16:01:00 | Endologix, Inc. to Present at the BMO Prescriptions for Success Healthcare Conference

2019-06-07 07:24:33 | The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

2019-06-06 16:01:00 | Endologix Announces Reinstatement of CE Mark for its Nellix EndoVascular Aneurysm Sealing System

2019-05-13 09:50:01 | Zacks.com featured highlights include: Avis, California Resources, Brinker, Endologix and Brookdale

2019-05-10 07:43:11 | 5 Broker-Friendly Stocks to Combat Market Jitters

2019-05-03 15:22:02 | Edited Transcript of ELGX earnings conference call or presentation 2-May-19 8:30pm GMT

2019-05-03 07:49:09 | The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen

2019-05-02 17:25:09 | Endologix ELGX Reports Q1 Loss, Tops Revenue Estimates

2019-05-02 16:18:25 | Endologix: 1Q Earnings Snapshot

2019-05-02 16:01:00 | Endologix Reports First Quarter 2019 Financial Results

2019-04-25 09:00:01 | Endologix ELGX Upgraded to Strong Buy: Here's Why

2019-04-15 16:01:00 | Endologix, Inc. to Announce First Quarter 2019 Financial Results on May 2, 2019

2019-04-15 12:58:32 | 5 Stocks to Profit From Legal Insider Buying Signals

2019-04-08 12:04:48 | Weekly CFO Buys Highlight

2019-04-03 19:15:04 | Endologix Inc ELGX CEO and Director John Onopchenko Bought $199,999 of Shares

2019-04-01 07:48:03 | Endologix Inc ELGX Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-04-01 07:30:00 | Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants

2019-03-20 16:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-03-06 07:39:22 | The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

2019-03-05 16:01:00 | Endologix Announces Approval of Reverse Stock Split

2019-02-27 10:00:43 | What Should We Expect From Endologix, Inc.’s NASDAQ:ELGX Earnings Over The Next Few Years?

2019-02-27 00:15:38 | Edited Transcript of ELGX earnings conference call or presentation 25-Feb-19 9:30pm GMT

2019-02-25 16:01:00 | Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results

2019-02-25 14:30:00 | Endologix, Inc. to Host Earnings Call

2019-02-22 09:48:02 | All You Need to Know About Endologix ELGX Rating Upgrade to Buy

2019-02-18 10:30:03 | Endologix ELGX Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2019-02-11 16:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-02-07 08:30:00 | Report: Developing Opportunities within Micron Technology, Endologix, Group 1 Automotive, Dana, MACOM Technology Solutions, and Fred's — Future Expectations, Projections Moving into 2019

2019-02-06 10:41:03 | WellCare Health WCG Q4 Earnings Beat Estimates, Soar Y/Y